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Introduction: No analyses have been reported on the impact of
visceral pleura invasion (VPI) on staging, in relation with the
International Association for the Study of Lung Cancer proposals for
the 7th edition of the tumor, node, metastasis (TNM) classification
of the International Union Against Cancer staging system. The
purpose of this study was to evaluate the impact of VPI on survival
and propose a method of incorporating VPI status into the TNM
classification.
Methods: We reviewed the data on 9758 non-small cell lung cancer
patients, who underwent anatomic surgical resection in 1999, accu-
mulated by the Japanese Joint Committee for Lung Cancer Regis-
tration, to gain insight into their clinicopathologic characteristics and
outcomes. VPI was defined as tumor extension beyond the elastic
layer of the visceral pleura. Patients were divided into nine groups
according to VPI status and tumor diameter, in accordance with the
International Association for the Study of Lung Cancer proposals.
Results: On the basis of survival, the nine groups were divided into
the following five levels: tumors2 cm without VPI; tumors2 cm
with VPI and tumors 2.1 to 3 cm without VPI; tumors 2.1 to 3 cm with
VPI and tumors 3.1 to 5 cm without VPI; tumors 3.1 to 5 cm with VPI
and tumors 5.1 to 7 cm without VPI; and tumors 5.1 to 7 cm with
VPI and tumors 7 cm without VPI or T3 tumors.
Conclusions: The T status of tumors, 7 cm or less, with VPI should
be upgraded to the next T level in the future edition of the TNM
classification of International Union Against Cancer staging system.
Key Words: Non-small cell lung cancer, Visceral pleura invasion,
TNM classification, Staging.
(J Thorac Oncol. 2009;4: 959–963)
Visceral pleura invasion (VPI) was adopted as a specificdescription in the tumor, node, metastasis (TNM) classi-
fication of the International Union Against Cancer (UICC)
staging system in the mid-1970s, but its status has remained
unchanged until today. A tumor of any size that does not
otherwise meet the criteria for a higher T category (e.g.,
associated atelectasis of the entire lobe or invasion to the
surrounding anatomic structure), which invades the visceral
pleura is classified as T2. Although a tumor 3 cm or less is
upgraded to T2, a tumor greater than 3 cm remains T2
according to this system, even if there is VPI.1 The Interna-
tional Association for the Study of Lung Cancer (IASLC)
proposals for the 7th edition of the TNM classification are
also the same. Although T1 tumors are subdivided by tumor
size at 2 cm into T1a (2 cm or less) and T1b (greater than 2
and 3 cm or less), the proposals do not subdivide tumors that
would otherwise be T1 but show VPI based on size and
classifies them inclusively as T2. Tumors with VPI greater
than 3 and 7 cm or less are classified as T2 in this system but
are not subdivided by tumor size, such as tumors without
VPI, into T2a (greater than 3 and 5 cm or less) or T2b (greater
than 5 and 7 cm or less).2
In 2004, Shimizu et al.3 and Osaki et al.4 reported on p1
pleural involvement, tumor extension beyond the elastic layer
of the visceral pleural but no exposure on the pleural surface
as defined by the Japan Lung Cancer Society (JLCS),5 as a
*Division of Thoracic Surgery, National Cancer Center Hospital East,
Kashiwa; †Division of Thoracic Surgery, National Cancer Center Hos-
pital, Tokyo; ‡Department of Surgery, Kyorin University School of
Medicine, Tokyo; §Department of Surgery, Jichi Medical School, Shi-
motsuke; Department of Internal Medicine, Teikyo University School of
Medicine, Tokyo; ¶Department of Pulmonary Medicine, Sapporo-Kosei
General Hospital, Sapporo; #Department of Clinical Medicine, Research
Institute for Diseases of the Chest, Kyushu University, Fukuoka; and
**Department of Mathematics, Science University of Tokyo, Tokyo,
Japan.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Junji Yoshida, MD, PhD, Division of Thoracic
Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha,
Kashiwa, Chiba, 277-8577, Japan. E-mail: jyoshida@east.ncc.go.jp
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0408-0959
Journal of Thoracic Oncology • Volume 4, Number 8, August 2009 959
prognostic factor and concluded that VPI should be defined as
tumor extension beyond the elastic layer of the visceral
pleura, regardless of its exposure on the pleural surface. On
the basis of the VPI definition, Shimizu et al. analyzed
survival in a large cohort of more than 1600 patients and
proposed that a tumor of 3 cm or less with VPI should remain
classified as a T2 tumor, as described in the current and
forthcoming UICC staging system, but tumors greater than 3
cm with VPI should be upgraded to T3.3
Since then, there have been several reports on TNM
classification regarding pleural involvement, but the authors
did not clearly define pleural invasion.6,7 No analyses have
been reported on the impact of VPI on staging in relation
to the IASLC proposals, for the 7th edition of the TNM
classification.
In 2005, 387 Japanese institutions submitted informa-
tion to the Japanese Joint Committee for Lung Cancer Reg-
istration regarding the outcome and clinicopathologic profiles
of patients who had undergone surgical resection for primary
lung cancers in the year 1999.8 We retrospectively analyzed
the survival of nearly 10,000 patients with pulmonary non-
small cell lung cancer (NSCLC) from this registration to
evaluate the impact of VPI on survival and to propose a
method of incorporating VPI into T-status classification in the




As described previously, the Japanese Joint Committee
for Lung Cancer Registration performed a nation-wide retro-
spective registry study, in 2005, on the outcome and clinico-
pathologic profiles of resected primary lung neoplasms in
Japan.8 Only primary lung cancers that had been resected in
1999 at certified teaching hospitals in Japan were considered
eligible for the registration, with a follow-up period of at least
5 years. The committee received the registries of 13,344
patients from 387 teaching hospitals. The registry question-
naire included the following items: gender, age, clinical
(c)-T, c-N, c-M, c-stage, preoperative treatment, surgical
procedure, extent of lymph node dissection, curability, resid-
ual tumor, primary site by lobe, tumor diameter, histology,
organ invasion, pathologic (p)-T, p-N, p-M, p-stage, pleural
involvement, pleural dissemination, intrapulmonary metasta-
sis, pleural cytology, location of nodal metastasis, survival
time, recurrence, and cause of death. Diseases were staged
based on the 6th edition of the UICC TNM classification.1
Histopathologic classification was described according to the
World Health Organization criteria.9 Recurrent or multiple
lung cancers were not included in the registration.
Only patients who underwent segmentectomy or more
extended lung resection were enrolled in this analysis. Pa-
tients with small cell carcinoma (390 patients, 2.9%), clini-
cally or pathologically detected distant metastases (617,
4.6%), with a T4 (608, 4.6%) or T0 (97, 0.7%) tumor and
those with incomplete data on VPI status (791, 5.9%), patho-
logic T (200, 1.5%) or N (121, 0.9%) status, were excluded,
leaving 9758 patients (73.1%) to be analyzed.
Analysis and Statistics
VPI was classified according to the JLCS criteria5: p0,
tumor with no pleural involvement beyond its elastic layer;
p1, tumor that extends beyond the elastic layer of the visceral
pleural but is not exposed on the pleural surface; and p2,
tumor that is exposed on the pleural surface but does not
involve adjacent anatomic structures. Pathologic p0 status
was defined as without VPI, whereas p1 and p2 were defined
as with VPI. All patients were divided into nine groups, A to
I, according to the VPI status (without or with) and tumor
diameter in accordance with the IASLC proposals for the 7th
edition of the TNM classification (2, 2.1–3, 3.1–5, 5.1–7, or
7 cm),2 and T3 factor as shown in Table 1.
We used Fisher’s exact test for comparing node in-
volvement rates, according to VPI, in each tumor size group.
Cumulative survival rates of patient groups A to I were
calculated by the Kaplan-Meier estimation method, using the
date of surgical resection as the starting point and the date of
TABLE 1. Nine Groups According to Tumor Diameter and VPI Status
Groups Tumor Diameter VPIa All Patients n (%) pN0 Patients n (%)
A 2 cm  2430 (24.9) 2153 (30.7)
B 2 cm  482 (4.9) 368 (5.2)
C 2.1–3 cm  1776 (18.2) 1394 (19.9)
D 2.1–3 cm  659 (6.8) 450 (6.4)
E 3.1–5 cm  1747 (17.9) 1128 (16.1)
F 3.1–5 cm  936 (9.6) 533 (7.6)
G 5.1–7 cm  305 (3.1) 187 (2.7)
H 5.1–7 cm  273 (2.8) 134 (1.9)
I T3 tumors as defined by the
UICC TNM classification,
7th edition
1150 (11.8) 672 (9.6)
Total 9758 (100) 7019 (100)
a VPI   p0, VPI   p1 or p2; p0, 1, 2 as defined by the Japan Lung Cancer Society classification of visceral pleura
invasion.
VPI, visceral pleura invasion; UICC, International Union Against Cancer; TNM, tumor, node, metastasis.
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death due to all causes or last follow-up date as the end point.
We also evaluated the survival of patients without lymph
node involvement (pN0) in each group. The difference in
survival was determined by log-rank analysis. A p value of
less than 0.05 was considered to indicate a statistically sig-
nificant difference. All statistical analyses were performed using
software packages (SAS version 8.2 [SAS Institute Inc., Cary,
NC], SPSS version 11.5 [SPSS Inc., Chicago, IL]).
This analysis was approved by the Japanese Joint Com-
mittee for Lung Cancer Registration in March 2008.
RESULTS
When nodal metastases rates according to VPI were
compared in each tumor size group, groups with VPI showed
significantly higher rates than groups without VPI (Table 1;
between groups A and B, p  0.001; C and D, p  0.001; E
and F, p  0.001; G and H, p  0.004). Table 2 shows the
patient characteristics. There were 3236 women and 6438
men, with gender information lacking in 84 patients, aged 15
to 90 years (mean 66 years). The extent of pulmonary
resection was pneumonectomy (n  390, 4.0%), lobectomy
(n  8829, 90.5%), and segmentectomy (n  539, 5.5%).
Histologic types were adenocarcinoma (n  6249, 64.0%),
squamous cell carcinoma (n  2839, 29.1%), large cell
carcinoma (n  333, 3.4%), adenosquamous carcinoma (n 
156, 1.6%), and others (n  181, 1.9%).
Survival Difference
The overall 5-year survival rates for groups A–I were
84.4, 69.9, 77.1, 62.5, 61.6, 53.0, 50.7, 45.2, and 40.7%,
respectively (Figure 1). There was no statistically significant
survival difference among groups D versus E (p  0.254),
groups F versus G (p  0.413), groups G versus H (p 
0.251), and groups H versus I (p  0.100). Survival was
significantly better in group A than C, C than B, B than D and
E, D and E than F and G, F than H, and G than I. Outcomes
were also examined in the pN0 patient cohort, and similar
relationships were observed.
DISCUSSION
Difficulty in diagnosing VPI has been repeatedly re-
ported.10,11 Although the JLCS recommends using not only
hematoxylin and eosin staining but also elastica staining like
Victoria-blue van Gieson staining in VPI evaluation, the
TABLE 2. Patient Characteristics
Characteristics
VPI
T3 or >7cm Total 
Age (yr)
Mean  SD 65.3  9.7 66.1  9.5 66.0  9.5 65.6  9.6
Range 15–90 27–88 29–90 15–90
Male/femalea (ratio) 3928/2271 (1.73) 1549/785 (1.97) 961/180 (5.34) 6438/3236 (1.99)
Type of operation (%)
Segmentectomy 423 (6.8) 89 (3.8) 27 (2.3) 539 (5.5)
Lobectomy 5646 (90.2) 2189 (93.1) 994 (86.4) 8829 (90.5)
Pneumonectomy 189 (3.0) 72 (3.1) 129 (11.2) 390 (4.0)
Histology (%)
Adenocarcinoma 4144 (66.2) 1655 (70.4) 450 (39.1) 6249 (64.0)
SCC 1718 (27.5) 547 (23.3) 574 (49.9) 2839 (29.1)
LCC 175 (2.8) 74 (3.1) 84 (7.3) 333 (3.4)
AdSq 83 (1.3) 52 (2.2) 21 (1.8) 156 (1.6)
Others 138 (2.2) 22 (0.9) 21 (1.8) 181 (1.9)
Tumor diameter (%)
2 cm 2430 (38.8) 482 (20.5) 42 (5.2) 2954 (31.4)
2.1–3 cm 1776 (28.4) 659 (28.0) 105 (13.0) 2540 (27.0)
3.1–5 cm 1747 (27.9) 936 (39.8) 419 (52.0) 3102 (33.0)
5.1–7 cm 305 (4.9) 273 (11.6) 239 (29.7) 817 (8.7)
Pathologic N status (%)
N0 4862 (77.7) 1485 (63.2) 672 (9.6%) 7019 (71.9)
N1 629 (10.1) 324 (13.8) 193 (16.8%) 1146 (11.7)
N2 731 (11.7) 520 (22.1) 271 (17.8%) 1522 (15.6)
N3 36 (0.6) 21 (0.9) 14 (19.7%) 71 (0.7)
Total (%) 6258 (64.1) 2350 (24.1) 1150 (11.8) 9758 (100.0)
a Data lacking for 84 (0.9%) patients.
SCC, squamous cell carcinoma; LCC, large cell carcinoma; AdSq, adenosquamous carcinoma; VPI, visceral pleura
invasion.
N0: No regional lymph node metastasis. N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes,
and intrapulmonary nodes including involvement by direct extension of the primary tumor. N2: Metastasis to ipsilateral
mediastinal and/or subcarinal lymph nodes. N3: Metastasis to contralateral mediastinal and/or supraclavicular lymph nodes.
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Japanese Joint Committee for Lung Cancer Registration did
not collect details of staining or how diligently VPI evalua-
tion was done in each participating institution.8 In 2004,
Shimizu et al.3 and Osaki et al.4 reported on p1 pleural
involvement as a prognostic factor and concluded that VPI
should be defined as tumor extension beyond the elastic layer
of the visceral pleura, regardless of its exposure on the pleural
surface. We decided to analyze the impact of VPI on staging
based on the VPI definition by Shimizu et al. and Osaki et al.
In this series, we analyzed the impact of VPI on
NSCLC patient survival to evaluate VPI impact on survival
and propose a method of incorporating VPI into T status, in
relation with the forthcoming 7th TNM classification.2 The
survival of patients with tumors 2 cm or less with VPI (group
B) was significantly worse than for patients with similarly
sized tumors without VPI (group A). Group B survival was
even worse than the survival of patients with tumors 2.1 to 3
cm without VPI (group C). However, it was significantly
better than the survival of patients with tumors 2.1 to 3 cm
with VPI (group D) and for patients with tumors 3.1 to 5 cm
without VPI (group E), which were identical. Similarly, the
survival of patients with tumors 2.1 to 3 cm with VPI (group
D) and for patients with tumors 3.1 to 5 cm without VPI
(group E) were significantly better than the survival of pa-
tients with VPI, who had tumors 3.1 to 5 cm (group F) and for
patients with tumors 5.1 to 7 cm without VPI (group G),
which were also identical. Although the survival of patients
with tumors 5.1 to 7 cm with VPI (group H) was not
significantly different from that of patients with tumors 5.1 to
7 cm without VPI (group G), the group H survival was
significantly worse than that of patients with tumors 3.1 to 5
cm with VPI (group F). Similarly, although the survival for
patients with T3 tumors or tumors greater than 7 cm (group
I) was not significantly different from that of patients with
tumors 5.1 to 7 cm with VPI (group H), the group I survival
was significantly worse than that of patients with tumors 5.1
to 7 cm who did not have VPI (group G).
These results indicate that tumors 2.1 to 3 cm and with
VPI (group D) should, unlike the IASLC proposals, be
classified as T2a, tumors 3.1 to 5 cm with VPI (group F) as
T2b, and tumors 5.1 to 7 cm with VPI (group H) as T3. As the
survival curve of tumors 2 cm or less with VPI (group B) was
significantly different from both that of group C and those of
groups D and E, creating another category such as T1c
appears ideal. Nevertheless, this will make what is already a
complicated T subclassification of T1/2 into T1a/1b/2a/2b even
more complicated. Although the 5-year survival rate of group B
fell right in the middle between that of group C and those of
groups D and E, the group B survival curve lay closer to the
group C curve until approximately 4 years after surgery. It seems
more appropriate to combine group B with the group C, classi-
fying them as T1b. This would also be consistent with other
tumors with VPI being upgraded to the next T level. To sum-
marize, the presence of VPI should upgrade T status to the next
level for all tumors 7 cm or less in size (Table 3).
It is not clear why VPI is associated with a worse
prognosis. Nodal metastases were significantly more frequent
in patients with VPI in each tumor size group in our cohort.
The finding supports the suggestion by Shimizu et al. that
there is a possible VPI tumor cell pathway through the
subpleural lymphatics, hilar lymph nodes, and into the me-
diastinal lymph nodes.3
Although this study is retrospective, it benefits from
being multiinstitutional and including a larger number of
TABLE 3. T Category Comparison





A 2 cm  T1a T1a
B 2 cm  T2 T1b
C 2.1–3 cm  T1b T1b
D 2.1–3 cm  T2 T2a
E 3.1–5 cm  T2a T2a
F 3.1–5 cm  T2a T2b
G 5.1–7 cm  T2b T2b
H 5.1–7 cm  T2(b) T3
a VPI   p0, VPI   p1 or p2; p0, 1, 2 as defined by the Japan Lung Cancer
Society classification of visceral pleura invasion.
VPI, visceral pleura invasion; IASLC, International Association for the Study of
Lung Cancer; TNM, tumor, node, metastasis.FIGURE 1. Survival curves and overall 5-year survival rates









A 2 cm  84.4
0.001
C 2.1–3 cm  77.1
]
0.002
B 2 cm  69.9
]
0.031
D 2.1–3 cm  62.5
]
0.254
E 3.1–5 cm  61.6
]
0.001
F 3.1–5 cm  53.0
]
0.413
0.021G 5.1–7 cm  50.7
]
0.251 ]
0.002H 5.1–7 cm  45.2
]
0.100 ]
I T3 tumors as defined
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patients than other surgical series. In 1999, when the patients
in this series underwent surgery, adjuvant chemotherapy was
not considered to be standard for NSCLC treatment. The
Japanese Joint Committee for Lung Cancer Registration did
not collect adjuvant treatment data,8 but it is speculated that
only a limited number of patients underwent adjuvant ther-
apy. Since 2004, after three trials (IALT, JBR 10, and
ANITA) that used cisplatin-based doublets and a UFT trial
showed a significantly positive survival benefit of adjuvant
chemotherapy in NSCLC patients, adjuvant chemotherapy
has been widely accepted as standard.12,13 In 2009, the Jap-
anese Joint Committee for Lung Cancer Registration plans to
collect information on patients who underwent surgical re-
section for primary lung neoplasms in 2004. However, many
of these patients especially in stages IB or more will have
undergone adjuvant chemotherapy. It will be difficult to
accumulate a larger cohort of patients, whose survival is not
affected by adjuvant chemotherapy, than that in this study.
In conclusion, this study indicates that the T status of
tumors 7 cm or less in size with VPI should be upgraded to
the next T level in the future edition of the TNM classification
of the UICC staging system.
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